10-K/A: Silence Therapeutics Amends 10-K to Include Part III Information and Updated Exhibits

Silence Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Summary

• Silence Therapeutics has filed Amendment No.
• 1 on Form 10-K/A to its Annual Report for the year ended December 31, 2024.
• The amendment includes information required by Items 10 through 14 of Part III of Form 10-K, which was previously omitted.
• Item 15 of Part IV of the Original 10-K has been amended to update the exhibit list.
• The company is including currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
• The amendment does not include new financial statements or amend any disclosure with respect to Items 307 and 308 of Regulation S-K.
• The company's board of directors consists of Craig Tooman, Iain Ross, James Ede-Golightly, Dave Lemus, and Michael Davidson.
• Craig Tooman serves as President, Chief Executive Officer, and Executive Director.
• Iain Ross is the Non-Executive Chairman.
• The board has four standing committees: Audit & Risk, Remuneration, Nominations, and Science & Technology.
• The company's executive officers are Craig Tooman, Rhonda Hellums, and Steven Romano, M.D.
• The company's executive compensation program aims to motivate, attract, and retain qualified executives, align incentives with employees and shareholders, and reward performance.
• The company's compensation program includes base salary, performance bonus, and long-term incentives.
• The company's non-executive director remuneration policy aims to attract and retain highly qualified directors.
• The company has adopted a related person transaction policy for the identification, review, and approval of related person transactions.
• The company's board of directors has determined that Iain Ross, James Ede-Golightly, Dave Lemus, and Michael Davidson are independent directors.
• The company has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by its independent registered public accounting firm, PwC.

Sentiment

Score: 7

Explanation: The document is primarily factual and informative, presenting details about the company's governance, executive compensation, and related matters. The sentiment is neutral to slightly positive, reflecting the company's efforts to comply with regulatory requirements and maintain good corporate governance practices.

Positives

• The company has a well-defined corporate governance structure with an independent board chair and various committees overseeing key functions.
• The company has a comprehensive executive compensation program designed to align executive incentives with shareholder interests and reward performance.
• The company has a related person transaction policy to ensure transparency and fairness in transactions involving related parties.
• The company has a pre-approval policy for audit and non-audit services to maintain auditor independence.

Risks

• The company's success depends on its ability to attract and retain qualified executives and directors.
• The company's compensation program may not be effective in motivating and retaining executives.
• Related person transactions could create conflicts of interest and harm the company's shareholders.
• The company's auditor may not be independent if it provides too many non-audit services.

Future Outlook

The company has approved corporate performance goals for 2025, which will be used to determine executive performance bonuses.

Industry Context

Silence Therapeutics operates in the biotechnology industry, focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid (siRNA). The company competes with other biotechnology and pharmaceutical companies in the development and commercialization of RNAi-based therapeutics.

Comparison to Industry Standards

• The document mentions benchmarking against peer companies to determine executive compensation.
• The peer group includes companies such as 4D Molecular Therapeutics, Immatics, Replimune Group, AC Immune SA, Iteos Therapeutics, Rocket Pharmaceuticals, Alpine Immune Sciences, Lineage Cell Therapeutics, Stoke Therapeutics, Autolus Therapeutics, Merus, Sutro Biopharma, Bicycle Therapeutics, Omega Therapeutics, Taysha Gene Therapies, Design Therapeutics, Poseida Therapeutics, Voyager Therapeutics, and Ikena Oncology.
• The Committee considers peer data as part of a market-check analysis that is used in conjunction with its assessments of numerous other factors.
• The Committees goal is to set our named executive officers target total cash compensation at the median of our peer group companies (with bonus more heavily weighted than salary) and to provide equity with a value between the 50th and 75th percentiles of our peer group.

Related Party Transactions

• The document describes transactions since January 1, 2023, with respect to which the company was a party, will be a party, or otherwise benefited, in which the amounts involved exceeded or will exceed $120,000 and a director, executive officer, holder of more than 5% of the company's ordinary shares or any member of their immediate family had or will have a direct or indirect material interest.

Stakeholder Impact

• The information in the amendment is relevant to shareholders as it provides details about the company's governance, executive compensation, and related matters.
• The company's employees are affected by the executive compensation program and the company's policies and procedures.
• The company's customers and suppliers may be affected by related person transactions.

Next Steps

• The company will continue to keep the registration statement effective until the Registrable Securities have been sold or may be resold pursuant to Rule 144 without restriction.
• Shareholders will have their first opportunity to cast a non-binding advisory vote (say-on-pay vote) to approve our named executive officers compensation at our 2025 meeting of shareholders.

Key Dates

Keywords

executive compensation, corporate governance, board of directors, audit committee, related party transactions, financial reporting, Silence Therapeutics, Form 10-K/A, directors, officers